Dashboard
Manage Tickers

DYN


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

oppenheimer-reiterates-outperform-on-dyne-therapeutics-maintains-47-price-target
Oppenheimer Reiterates Outperform on Dyne ...
03/26/2024 14:07:28

Oppenheimer analyst Francois Brisebois reiterates Dyne Therapeutics (NASDAQ:DYN) with a Outperform and maintains $47 price t...

why-landos-biopharma-shares-are-trading-higher-by-over-170-here-are-other-stocks-moving-in-mondays-mid-day-session
Why Landos Biopharma Shares Are Trading Hi...
03/25/2024 18:44:08

Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news.

aehr-test-systems-reports-preliminary-results-joins-dyne-therapeutics-united-airlines-and-other-big-stocks-moving-lower-on-monday
Aehr Test Systems Reports Preliminary Resu...
03/25/2024 14:32:02

U.S. stocks were lower, with the Dow Jones index falling around 100 points on Monday.

dyne-therapeutics-has-appointed-john-cox-as-president-chief-executive-officer-and-a-member-of-the-board-of-directors-effective-immediately-he-succeeds-joshua-brumm-who-has-chosen-to-step-down
Dyne Therapeutics Has Appointed John Cox A...
03/25/2024 11:34:39

neuromuscular-focused-avidity-biosciences-has-complete-package---analyst-predicts-stellar-142-stock-surge
Neuromuscular Focused-Avidity Biosciences ...
03/14/2024 19:29:25

Cantor Fitzgerald initiates coverage on Avidity Biosciences highlighting a robust pipeline led by del-desiran, a promising trea...

chardan-capital-maintains-buy-rating-for-dyne-therapeutics-heres-what-you-need-to-know
Chardan Capital Maintains Buy Rating for D...
03/08/2024 17:00:24

chardan-capital-maintains-buy-on-dyne-therapeutics-raises-price-target-to-31
Chardan Capital Maintains Buy on Dyne Ther...
03/08/2024 08:58:16

Chardan Capital maintains Dyne Therapeutics (NASDAQ:DYN) with a Buy and raises the price target from $20 to $31.

guggenheim-maintains-buy-on-dyne-therapeutics-raises-price-target-to-37
Guggenheim Maintains Buy on Dyne Therapeut...
03/07/2024 16:19:00

Guggenheim analyst Debjit Chattopadhyay maintains Dyne Therapeutics (NASDAQ:DYN) with a Buy and raises the price target from...

hc-wainwright--co-reiterates-buy-on-dyne-therapeutics-maintains-36-price-target
HC Wainwright & Co. Reiterates Buy on Dyne...
03/06/2024 17:59:00

HC Wainwright & Co. analyst Andrew Fein reiterates Dyne Therapeutics (NASDAQ:DYN) with a Buy and maintains $36 price tar...

piper-sandler-maintains-overweight-rating-for-dyne-therapeutics-heres-what-you-need-to-know
Piper Sandler Maintains Overweight Rating ...
03/06/2024 17:00:14

stifel-maintains-buy-on-dyne-therapeutics-raises-price-target-to-41
Stifel Maintains Buy on Dyne Therapeutics,...
03/06/2024 15:24:04

Stifel analyst Paul Matteis maintains Dyne Therapeutics (NASDAQ:DYN) with a Buy and raises the price target from $35 to $41.

piper-sandler-maintains-overweight-on-dyne-therapeutics-raises-price-target-to-29
Piper Sandler Maintains Overweight on Dyne...
03/06/2024 14:27:57

Piper Sandler analyst Edward Tenthoff maintains Dyne Therapeutics (NASDAQ:DYN) with a Overweight and raises the price target...

oppenheimer-reiterates-outperform-on-dyne-therapeutics-raises-price-target-to-47
Oppenheimer Reiterates Outperform on Dyne ...
03/05/2024 12:52:42

Oppenheimer analyst Francois Brisebois reiterates Dyne Therapeutics (NASDAQ:DYN) with a Outperform and raises the price targ...

recap-dyne-therapeutics-q4-earnings
Recap: Dyne Therapeutics Q4 Earnings
03/05/2024 12:40:05

dyne-therapeutics-q4-eps-109-misses-092-estimate-cash-balance-of-1231m
Dyne Therapeutics Q4 EPS $(1.09) Misses $(...
03/05/2024 12:36:37

Dyne Therapeutics (NASDAQ:DYN) reported quarterly losses of $(1.09) per share which missed the analyst consensus estimate of $(...

cooper-companies-reports-upbeat-results-joins-dell-netapp-tidewater-and-other-big-stocks-moving-higher-on-friday
Cooper Companies Reports Upbeat Results, J...
03/01/2024 16:18:21

U.S. stocks were higher, with the Nasdaq Composite gaining around 0.5% on Friday.

hc-wainwright--co-initiates-coverage-on-dyne-therapeutics-with-buy-rating-announces-price-target-of-36
HC Wainwright & Co. Initiates Coverage On ...
02/20/2024 13:03:17

HC Wainwright & Co. analyst Andrew Fein initiates coverage on Dyne Therapeutics (NASDAQ:DYN) with a Buy rating and annou...

top-4-health-care-stocks-you-may-want-to-dump-in-february
Top 4 Health Care Stocks You May Want To D...
02/15/2024 13:15:49

As of Feb. 15, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as ...

dyne-therapeutics-announces-upcoming-presentations-on-initial-clinical-data-from-its-achieve-trial-in-dm1-patients-and-deliver-trial-in-dmd-patients-at-the-2024-muscular-dystrophy-association-clinical--scientific-conference
Dyne Therapeutics Announces Upcoming Prese...
02/14/2024 22:09:29

- Presentations will Highlight Initial Data Announced in January 2024 Demonstrating Proof-of-Concept in its DM1 and DMD Program...

drug-developer-dyne-therapeutics-weigh-options-after-takeover-interest--bloomberg
'Drug Developer Dyne Therapeutics Weigh Op...
01/26/2024 19:50:57

https://www.bloomberg.com/news/articles/2024-01-26/dyne-therapeutics-said-to-weigh-options-amid-takeover-interest?cmpid=socialf...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION